Abstract
Background: Monitoring the adaptive immune responses during the natural course of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection provides useful information for the development of vaccination strategies against this virus and its emerging variants. We thus profiled the serum anti-SARS-CoV-2 antibody (Ab) levels and specific memory B and T cell responses in convalescent coronavirus disease 2019 (COVID-19) patients.
Methods: A total of 119 samples from 88 convalescent donors who experienced mild to critical disease were tested for the presence of elevated anti-spike and anti-receptor binding domain Ab levels over a period of 8 months. In addition, the levels of SARS-CoV-2 neutralizing Abs and specific memory B and T cell responses were tested in a subset of samples.
Findings: Anti-SARS-CoV-2 Abs were present in 85% of the samples collected within 4 weeks after the onset of symptoms in COVID-19 patients. Levels of specific immunoglobulin M (IgM)/IgA Abs declined after 1 month, while levels of specific IgG Abs and plasma neutralizing activities remained relatively stable up to 6 months after diagnosis. Anti-SARS-CoV-2 IgG Abs were still present, although at a significantly lower level, in 80% of the samples collected at 6-8 months after symptom onset. SARS-CoV-2-specific memory B and T cell responses developed with time and were persistent in all of the patients followed up for 6-8 months.
Conclusions: Our data suggest that protective adaptive immunity following natural infection of SARS-CoV-2 may persist for at least 6-8 months, regardless of disease severity. Development of medium- or long-term protective immunity through vaccination may thus be possible.
Funding: This project was supported by the European Union’s Horizon 2020 research and innovation programme (ATAC, no. 101003650), the Italian Ministry of Health (Ricerca Finalizzata grant no. GR-2013-02358399), the Center for Innovative Medicine, and the Swedish Research Council. J.A. was supported by the SciLifeLab/KAW national COVID-19 research program project grant 2020.
Keywords: B cell; COVID-19; IgG; SARS-CoV-2; T cell; antibody; immunity; immunological memory; longevity of immune response; neutralizing antibody.
【저자키워드】 COVID-19, SARS-CoV-2, IgG, Immunity, antibody, Immunological memory, B cell, T cell, neutralizing antibody., longevity of immune response, 【초록키워드】 coronavirus disease, neutralizing antibody, Coronavirus disease 2019, immune response, vaccination, adaptive, antibody, disease severity, Infection, Diagnosis, severe acute respiratory syndrome coronavirus-2, severe acute respiratory syndrome Coronavirus, virus, Immunological memory, variants, immune, B cell, Medicine, serum, Neutralizing activity, T cell, Immunoglobulin, anti-SARS-CoV-2 antibody, protective immunity, anti-SARS-CoV-2 IgG, immune responses, T cell responses, Research, Vaccination strategies, Mild, plasma, monitoring, Neutralizing, Adaptive immune response, respiratory, convalescent, Longevity, information, development, natural infection, patients, T cell response, COVID-19 patients, Anti-spike, Protective, Donor, Critical disease, Coronavirus-2, adaptive immune responses, Vaccination strategy, immunoglobulin M, symptom onset, acute respiratory syndrome, acute respiratory syndrome coronavirus, medium, acute respiratory syndrome coronavirus-2, center, union, Horizon, binding domain, National, COVID-19 research, significantly lower, Council, Ministry of Health, European, immunological, Italian, memory B, Course, tested, collected, the patient, addition, remained, elevated, supported, onset of symptom, provide, Swedish, subset, Level, declined, 【제목키워드】 Infection, T cell, T cell response, convalescent COVID-19 patient,